All Medicines
Dr. Aditya Singh

Medically Reviewed By

Dr. Aditya Singh, MBBS, MD (Pharmacology)

Reg No: MCI-654321 • Verified Medical Reviewer

Antineoplastic agents

Brukinsa

(zanubrutinib)

Uses, side effects, dosage information & price range

BeOne Medicines Ireland Limited

About this medicine

Brukinsa as monotherapy is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. Brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy. Brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL). Brukinsa in combination with obinutuzumab is indicated for the treatment of adult patients with refractory or relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.

Key Information

Salt / Composition

zanubrutinib

Category

Antineoplastic agents

Manufacturer

BeOne Medicines Ireland Limited

Need a doctor's consultation?

Don't self-medicate. Consult a doctor before taking any medicine.

Medical Disclaimer

This information is for educational purposes only and is not a substitute for professional medical advice. Always consult your doctor or pharmacist before taking any medication. Prices are indicative and may vary. Do not start, stop, or change the dosage of any medicine without your doctor's approval.

Disclaimer:Content on this page is for informational purposes only. Do not consume prescription medication without a registered practitioner's direct oversight.